Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
Guru SonpavdeUS Oncology Research, Inc., Houston, TX; Texas Oncology PA, Webster, TX. Electronic address: [email protected]Phillip PerimanUS Oncology Research, Inc., Houston, TX; Texas Oncology PA, Amarillo, TXD. M. BernoldUS Oncology Research, Inc., Houston, TX; Interlakes Oncology Hematology, Rochester, NYDouglas WecksteinUS Oncology Research, Inc., Houston, TX; New Hampshire Hematology-Oncology, P.A., Hooksett, NHMark T. FlemingUS Oncology Research, Inc., Houston, TX; Virginia Oncology Associates, Hampton, VAMatthew D. GalskyUS Oncology Research, Inc., Houston, TX; Comprehensive Cancer Centers of Nevada, Las Vegas, NVWilliam R. BerryUS Oncology Research, Inc., Houston, TX; Cancer Centers of North Carolina, Raleigh, NCFeng ZhanUS Oncology Research, Inc., Houston, TXKristi A. BoehmUS Oncology Research, Inc., Houston, TXLina AsmarUS Oncology Research, Inc., Houston, TXThomas E. HutsonUS Oncology Research, Inc., Houston, TX; Baylor Sammons Cancer Center, Dallas, TX, USA
2009en
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba